Targeted CAR-T cell therapy for advanced lymphoma or leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must be between 14 and 85 years old and expected to live at least 3 more months.
- Your cancer cells must have both CD19 and CD22 proteins on their surface (a lab test can check this).
- Your lymphoma or leukemia must have come back or not responded to standard first treatment.
- You must be feeling well enough to perform daily activities (ECOG score 0–2) and have at least one tumor that can be measured on scans.
- Your heart, liver, kidneys, and blood counts (white cells, red cells, platelets) must be in a healthy enough range.
- You cannot be pregnant, have an active uncontrolled infection, or have had a previous gene therapy treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
This study tests a new type of immune therapy called CAR-T cells, which are made from your own blood cells to find and attack cancer. It is for adults with leukemia or lymphoma that has come back or is hard to treat.
This trial tests a new type of immunotherapy called CAR-T cells, which are made from your own blood cells and trained to find and destroy leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
Hear when a new B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.